The stock speculation lost more than 76 million yuan! The pharmaceutical company with a market value of 18 billion yuan announced: increase its position, up to 1 billion yuan
Recently, a number of listed companies have released idle fund management plans.
On the evening of April 16, Jilin Aodong (000623) announced that it planned to use no more than 1 billion yuan of idle own funds for securities investment.
Jilin Aodong said that under the premise of not affecting the development of the company's main business, ensuring the normal operation of the company's capital needs, and ensuring the safety of funds and controllable risks, in order to further strengthen the management of securities assets and idle own funds held by the company and its holding subsidiaries, improve the efficiency of the company's capital use, rationally use idle own funds, and strive to maximize the company's and shareholders' returns.
Jilin Aodong's 2023 annual report shows that the company's returns on securities investment are not ideal. Last year, Jilin Aodong held a total of Liaoning Chengda (600739. SH), the First Hospital (600833. SH), Nanjing Pharmaceutical (600713. SH), Luye Pharma (02186. HK) and other 9 domestic and foreign stocks, with an initial investment cost of 2.732 billion yuan, will increase its position by 458 million yuan in 2023, but the loss for the year will reach 76.58 million yuan.
Among them, Jilin Aodong has a heavy position in Liaoning Chengda, with an initial investment cost of 2.037 billion yuan, a book value of 977 million yuan at the beginning of 2023, and an increase of 279 million yuan in that year, and a book value of 1.172 billion yuan at the end of the period. In addition, Jilin Aodong will invest in First Pharmaceutical in 2023 and earn 11.41 million yuan.
Jilin Aodong announced that as of December 31, 2023, the company and its subsidiary Yanbian Pharmaceutical held a total of 99479276 shares of Liaoning Chengda, accounting for 6.50% of the total share capital of Liaoning Chengda, directly held 10988525 shares of First Pharmaceutical, accounting for 4.93% of the total share capital of First Pharmaceutical, and directly held 19094156 shares of Nanjing Pharmaceutical, accounting for 1.46% of the total share capital of Nanjing Pharmaceutical, and the company is also a shareholder of listed companies such as Luye Pharmaceutical.
As of the end of 2023, Jilin Aodong's financial assets were 1.658 billion yuan, and the fair value change decreased by 111 million yuan last year.
In terms of performance, in 2023, Jilin Aodong will achieve operating income of 3.449 billion yuan, an increase of 20.25% year-on-year, and net profit attributable to the parent company of 1.460 billion yuan, a year-on-year decrease of 18.02%. The profit distribution plan deliberated and approved by the board of directors is: based on the total share capital on the equity registration date at the time of the implementation of the company's equity distribution in 2023, a cash dividend of 6 yuan (tax included) will be distributed to all shareholders for every 10 shares.
Securities investment is an important business in Jilin Aodong in addition to medicine, Jilin Aodong said that the company with the "medicine + finance + health" multi-wheel drive operation model, has invested in a number of distinctive characteristics, outstanding advantages and strong competitiveness of pharmaceutical and biological listed companies, seeking further cooperation in pharmaceutical and biological industry projects, and promoting the synchronization of production and research.
According to the official website of Jilin Aodong, the predecessor of the company was the state-owned Yanbian Dunhua Deer Farm established in 1957, and the Aodong Pharmaceutical Factory was established in 1981, and in 1993, with the approval of the Jilin Provincial Economic System Reform Commission, Yanbian Aodong Pharmaceutical (Group) Co., Ltd. was established, and in 1998, it was renamed Jilin Aodong Pharmaceutical Group Co., Ltd., and was listed on the Shenzhen Stock Exchange on October 28, 1996. In 2001, Jilin Aodong established a parent-subsidiary system, and gradually developed into a holding group listed company based on the pharmaceutical industry and with the rapid development of the multi-wheel drive model of "medicine + finance + health". At present, the company holds a total of 21 subsidiaries, including 6 professional pharmaceutical subsidiaries engaged in modern traditional Chinese medicine, biochemical drugs and phytochemical drugs, 1 pharmaceutical R&D subsidiary, 5 pharmaceutical sales subsidiaries, 5 pharmaceutical supporting subsidiaries, 2 high-end health care products companies, 1 highway construction toll company, and 1 Aodong International (Hong Kong) Industrial Co., Ltd.
As of the close of trading on April 17, the share price of Jilin Aodong was 14.52 yuan, with a total market value of 18.02 billion yuan.
According to the Securities Times, recently, the A-share market has ushered in a "wealth management fever", and many companies have successively thrown out their 2024 financial management plans, mostly focusing on wealth management products or bond products, focusing on "high security". On April 16, Yingke Regeneration, VIE Technology, Beijing Cree and others announced that they planned to use their own idle funds for investment and financial management, and purchase low-risk financial products with high security and good liquidity, ranging from 100 million to 200 million yuan.
Earlier this year, many companies disclosed wealth management quotas of 5 billion yuan or more. For example, BYD announced on March 26 that the company and its holding subsidiaries intend to use their own idle funds to purchase high-security, liquidity, low-risk wealth management products or bond products in banks, securities companies, fund companies, insurance asset management companies and other financial institutions, with a total amount of funds not exceeding RMB 60 billion, and the authorized use period is within 12 months from the date of approval by the board of directors.
Also on March 26, SF Holding announced that the company held the 12th meeting of the 6th board of directors and the 8th meeting of the 6th board of supervisors, and deliberated and approved the "Proposal on Using Own Funds to Purchase Wealth Management Products in 2024", with an investment amount of no more than RMB 45 billion, and funds can be recycled within this limit. The investment types are low-risk wealth management products issued by banks and other financial institutions, including structured deposits, low-risk fixed-income wealth management, etc.
China Grain Flow announced that on March 25, the fourth meeting of the company's third board of directors and the third meeting of the third board of supervisors deliberated and passed the "Proposal on the Use of Own Funds for Short-term Entrusted Financial Management in 2022". The Company and its subsidiaries intend to use their own funds of no more than RMB 10 billion to carry out staged entrusted wealth management, which can be used on a rolling basis for a period of no more than one year. The entrusted wealth management products are limited to the wealth management products sold by financial institutions with legal business qualifications. It shall not be used to invest in stocks and their derivatives, securities investment funds and entrusted wealth management products for the purpose of securities investment.
Shuanghui Development announced on March 26 that the company held the 20th meeting of the 8th board of directors on March 23, 2024, and deliberated and passed the "Proposal on Carrying out Investment and Wealth Management Business", and agreed that the company and its holding subsidiaries should carry out investment and wealth management business, with a transaction amount of no more than 6 billion yuan, and the funds within the limit can be recycled, and the transaction amount at any point in time during the validity period shall not exceed the aforementioned amount.
Disclaimer: The content and data of the article are for reference only and do not constitute investment advice. Investors act accordingly at their own risk.
Editor|Sun Zhicheng, Gai Yuanyuan, Du Hengfeng
Proofreading|Cheng Peng
The cover image is from Visual China
Daily Economic News, comprehensive public information, Securities Times, etc
National Business Daily